FILTER
FILTERED INTERVIEW RESULTS
Asimwe Kabunga
CHAIRMAN, LINDIAN RESOURCES
Lindian Resources is extending its portfolio of assets in Africa from bauxite in Guinea to rare earths in Malawi.
Asimwe Kabunga
CHAIRMAN, LINDIAN RESOURCES LIMITED
"With near-term export options, exceptional quality material and a multi-generational resource base, Lindian is well placed to become the best bauxite development company in the world."
Dolores Biamou
MINING PROJECTS DIRECTOR AFRICA, BOLLORÉ LOGISTICS
Bolloré Logistics explains how it has been able to maintain the supply chain for mines in Africa despite the pandemic and security threats.
John Kwofie & Ivan Doku
PRINCIPAL MINING ENGINEER AND COUNTRY MANAGER & PRINCIPAL RESOURCE GEOLOGIST AND COUNTRY MANAGER-DESIGNATE, SRK CONSULTING
An overview of the firm’s activities in West Africa.
Todd Burns
PRESIDENT, CYPHER ENVIRONMENTAL
Cypher Environmental provides solutions for stabilizing roads and suppressing dust in an environmentally friendly manner.
Paul Roberts
MANAGING DIRECTOR, PREDICTIVE DISCOVERY
Predictive Discovery explains progress at its Bankan discovery in Guinea, which holds a special place in the company’s West African portfolio.
Martin van Gemert
MANAGING DIRECTOR, MINCON WEST AFRICA
Mincon comments on its business with the mining sector in West Africa.
Danny Callow
CEO, AFRICAN GOLD GROUP (AGG)
African Gold Group explains its ambitions in West Africa where it’s Kobada gold mine is under construction.
Martin van Gemert
MANAGING DIRECTOR, MINCON WEST AFRICA
Mincon West Africa is an engineering company that specializes in hard-rock drilling tools.
Joel Cavaille & Samuel Modicom
CEO, JA DELMAS & COUNTRY MANAGER, SAUDEQUIP
Saudequip supplies the Caterpillar brand across francophone West Africa and is benefitting from the region’s current boom in mining.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENTLY PUBLISHED
United States Life Sciences 2023
In many ways, 2022 was a turning point for the US life sciences industry. After having provided a lightning-quick response to the Covid-19 pandemic, the industry gathered the lessons learned and sought a sense of normalcy to continue developing necessary drugs for patients worldwide. Yet, the geopolitical, macroeconomic, and regulatory environments all come with their set of challenges, forcing executives into increasingly complex decisions when defining their strategies.
In many ways, 2022 was a turning point for the US life sciences industry. After having provided a lightning-quick response to the Covid-19 pandemic, the industry gathered the lessons learned and sought a sense of normalcy to continue developing necessary drugs for patients worldwide. Yet, the geopolitical, macroeconomic, and regulatory environments all come with their set of challenges, forcing executives into increasingly complex decisions when defining their strategies.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
